



FOR IMMEDIATE RELEASE

Zingo® for Needle-free Local Analgesia is approved by Hong Kong Department of Health

[18 August 2017, Hong Kong] Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China is pleased to announce that Powder Pharmaceuticals, Incorporated ("PPI"), an associated company of the Group, has obtained product registration certificate of Zingo® from Hong Kong Department of Health (DH).

"We are pleased that Hong Kong DH has approved Zingo® product registration," said Dr. Benjamin Li, Chief Executive Officer of the Group. "Zingo® is currently only marketing in the U.S. We will launch the product in Hong Kong very soon so that more needle phobic children and adults in Hong Kong can be benefited from this novel needle-free local analgesia." Zingo® is the first new drug product that is made in Hong Kong. Our facility is the only one in Hong Kong that is GMP certified for both FDA and PIC/S for new drug manufacturing.

About Zingo®

Zingo® (lidocaine hydrochloride monohydrate) is an amide local anesthetic indicated for use on intact skin to provide local analgesia prior to venipuncture or peripheral intravenous cannulation in children 3–18 years of age and to provide topical local analgesia prior to venipuncture in adults. The rapid onset of analgesia in 1-3 minutes provides care givers and patients the opportunity for a pain-free and needle-free access procedure. Clinical trials have shown a statistical difference in pain scores during needle access procedures when using Zingo® versus a placebo system. Zingo® is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type. It is not to be used around the eyes or on body orifices, mucous membranes, or on areas with a compromised skin barrier.

About Powder Pharmaceuticals, Incorporated

Powder is an associated company of Lee's Pharmaceutical Holdings Limited based in Hong Kong and is developing products that utilize a proprietary needleless, painless, powder delivery technology. Powder intends to supply Zingo® globally through international business partners. Powder has successfully obtained approval from U.S. FDA in July 2013 for the manufacturing facilities in Hong Kong to produce Zingo® and market the product to U.S.

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a research-based biopharmaceutical company listed in Hong Kong with more than 20 years of operation in China's pharmaceutical industry. It is fully integrated with a strong infrastructure in drug development, manufacturing, sales and marketing. It has established extensive partnerships with more than 20 international companies and currently has 15 products in the market place. Lee's Pharmaceutical focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. The company's development program is lauded with over 40 product candidates stemming from both internal R&D efforts and collaborations with US, European and Japanese companies, including promising compounds to treat liver cancer and pulmonary hypertension. The mission of Lee's Pharmaceutical is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information is available at <http://www.leespharm.com>.

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialize or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com